Hauptmenü:
Vardenafil is primarily metabolized by CYP3A; ceritinib is a strong CYP3A inhibitor. Use of vardenafil with other strong CYP3A inhibitors increased the AUC of vardenafil by 10 to 16-fold. There may also be an increased potential for QT prolongation. Vardenafil can produce an increase in QTc interval at both therapeutic and supratherapeutic doses. Ceritinib has been reported to cause concentration-dependent QT prolongation. Periodically monitor ECGs and electrolytes during concurrent use of ceritinib and vardenafil oral tablets. Chloramphenicol: (Major) Do not use vardenafil orally disintegrating tablets with chloramphenicol due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; chloramphenicol is a strong CYP3A4 inhibitor. Chloroquine: (Major) Concomitant use of vardenafil and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Chlorpheniramine; Dextromethorphan; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Chlorpheniramine; Dihydrocodeine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Chlorpheniramine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Chlorpromazine: (Major) Concomitant use of vardenafil and chlorpromazine increases the risk of QT/QTc prolongation and torsade de pointes (TdP).
| Condition | Caution | Reason |
|---|---|---|
| Use with Nitrates | Contraindicated | Risk of severe hypotension |
| Severe Liver Impairment | Use with caution | Metabolism may be affected |
| Heart Disease | Consult doctor before use | Potential cardiovascular risks |
| Retinitis Pigmentosa | Avoid | Possible risk of vision loss |
| Hypotension or Hypertension | Caution or avoid | Blood pressure effects |
Ciprofloxacin: (Major) Do not use vardenafil orally disintegrating tablets with ciprofloxacin due to increased vardenafil exposure; do not exceed buy levitra no prescription a single dose of 5 mg per 24-hour period of vardenafil oral tablets.
Disopyramide: (Major) Vardenafil should be avoided in patients taking Class IA antiarrhythmics (disopyramide, procainamide, and quinidine). Dofetilide: (Major) Concomitant use of vardenafil and dofetilide increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Dolasetron: (Moderate) Concomitant use of vardenafil and dolasetron may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Dolutegravir; Rilpivirine: (Moderate) Concomitant use of vardenafil and rilpivirine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Donepezil: (Moderate) Concomitant use of vardenafil and donepezil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Vardenafil is primarily metabolized by CYP3A and ciprofloxacin is a moderate CYP3A inhibitor. Cisapride: (Contraindicated) Avoid concomitant use of vardenafil and cisapride due to an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. Citalopram: (Major) Concomitant use of citalopram and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Clarithromycin: (Major) Do not use vardenafil orally disintegrating tablets with clarithromycin due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Class IA Antiarrhythmics: (Major) Vardenafil should be avoided in patients taking Class IA antiarrhythmics (disopyramide, procainamide, and quinidine). Class IA antiarrhythmics are associated with QT prolongation and torsade de pointes (TdP). Therapeutic and supratherapeutic doses of vardenafil produce an increase in QTc interval. The effect of vardenafil on the QT interval should be considered when prescribing the drug. Clofazimine: (Moderate) Concomitant use of clofazimine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Clozapine: (Moderate) Concomitant use of vardenafil and clozapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Levitra Original | 20mg | 76 + 4 Pills | 344.39€ 327.99€ | |
| Levitra Generic | 10mg | 180 + 10 Pills | 246.74€ 234.99€ | |
| Levitra Professional | 20mg | 180 + 4 Pills | 502.31€ 478.39€ | |
| Levitra Generic | 10mg | 90 + 8 Pills | 150.58€ 143.41€ | |
| Levitra Generic | 20mg | 30 + 4 Pills | 70.59€ 67.23€ | |
| Levitra Generic | 40mg | 10 Pills | 41.37€ 39.40€ | |
| Levitra Original | 20mg | 64 + 4 Pills | 298.45€ 284.24€ | |
| Levitra Generic | 20mg | 270 + 10 Pills | 376.33€ 358.41€ | |
| Levitra Generic | 20mg | 360 + 10 Pills | 458.44€ 436.61€ | |
| Levitra Generic | 60mg | 180 + 10 Pills | 501.43€ 477.55€ | |
| Levitra Professional | 20mg | 360 + 6 Pills | 914.63€ 871.08€ | |
| Levitra Soft Tabs | 20mg | 360 + 20 Pills | 682.21€ 649.72€ | |
| Levitra Generic | 40mg | 30 + 2 Pills | 93.58€ 89.12€ | |
| Levitra Generic | 40mg | 360 + 10 Pills | 704.99€ 671.42€ | |
| Levitra Original | 20mg | 34 + 2 Pills | 188.51€ 179.53€ | |
| Levitra Generic | 60mg | 120 + 8 Pills | 372.33€ 354.60€ |
Cobicistat: (Major) Do not use vardenafil orally disintegrating tablets with cobicistat due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Codeine; Phenylephrine; Promethazine: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Codeine; Promethazine: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Conivaptan: (Major) Do not use vardenafil orally disintegrating tablets with conivaptan due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets.
Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: (Major) Do not use vardenafil orally disintegrating tablets with cobicistat due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Dasatinib: (Moderate) Concomitant use of vardenafil and dasatinib may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Degarelix: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., degarelix) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Delavirdine: (Major) Do not use vardenafil orally disintegrating tablets with delavirdine due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; delavirdine is a strong CYP3A4 inhibitor.
Deutetrabenazine: (Moderate) Consider the potential for additive QT effects if vardenafil is administered with deutetrabenazine. Deutetrabenazine may prolong the QT interval, but the degree of QT prolongation is not clinically significant when deutetrabenazine is administered within the recommended dosage range. Dexmedetomidine: (Moderate) Concomitant use of dexmedetomidine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Dextromethorphan; Diphenhydramine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Dextromethorphan; Guaifenesin; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors.
Dextromethorphan; Quinidine: (Major) Vardenafil should be avoided in patients taking Class levitra 100 mg IA antiarrhythmics (disopyramide, procainamide, and quinidine). Diltiazem: (Major) Do not use vardenafil orally disintegrating tablets with diltiazem due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Additive effects on blood pressure are also possible. Vardenafil is primarily metabolized by CYP3A and diltiazem is a moderate CYP3A inhibitor. Diphenhydramine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Vardenafil is primarily metabolized by CYP3A; conivaptan is a moderate CYP3A inhibitor. Crizotinib: (Major) Do not use vardenafil orally disintegrating tablets with crizotinib due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; crizotinib is a moderate CYP3A4 inhibitor. In addition, vardenafil is associated with QT prolongation. Both therapeutic and supratherapeutic doses of vardenafil may produce an increase in QTc interval. Crizotinib has also been associated with concentration-dependent QT prolongation. Monitor ECGs and electrolytes levitra now online if crizotinib and vardenafil oral tablets are used together. Cyclosporine: (Major) Do not use vardenafil orally disintegrating tablets with cyclosporine due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets.
Vardenafil is primarily metabolized by CYP3A4/5; cyclosporine is a moderate CYP3A4 inhibitor. Danazol: (Major) Do not use vardenafil orally disintegrating tablets with danazol due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; danazol is a moderate CYP3A4 inhibitor. Darunavir: (Major) Do not use vardenafil orally disintegrating tablets with darunavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets.
Crizotinib: (Major) Do not use vardenafil orally disintegrating tablets with crizotinib due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; crizotinib is a moderate CYP3A4 inhibitor. In addition, vardenafil is associated with QT prolongation. Both therapeutic and supratherapeutic doses of vardenafil may produce an increase in QTc interval. Crizotinib has also been associated with concentration-dependent QT prolongation.
Monitor ECGs and electrolytes levitra now online if crizotinib and vardenafil oral tablets are used together. Cyclosporine: (Major) Do not use vardenafil orally disintegrating tablets with cyclosporine due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; cyclosporine is a moderate CYP3A4 inhibitor. Danazol: (Major) Do not use vardenafil orally disintegrating tablets with danazol due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; danazol is a moderate CYP3A4 inhibitor.
Darunavir: (Major) Do not use vardenafil orally disintegrating tablets with darunavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; darunavir is a strong CYP3A4 inhibitor. Coadministration with other strong CYP3A4 inhibitors increased the AUC of vardenafil by 10- to 16-fold. Darunavir; Cobicistat: (Major) Do not use vardenafil orally disintegrating tablets with cobicistat due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. (Major) Do not use vardenafil orally disintegrating tablets with darunavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; darunavir is a strong CYP3A4 inhibitor. Coadministration with other strong CYP3A4 inhibitors increased the AUC of vardenafil by 10- to 16-fold.
Donepezil; Memantine: (Moderate) Concomitant use of vardenafil and donepezil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Doxazosin: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on alpha-blocker therapy before initiating therapy with the lowest dose of vardenafil. Dronedarone: (Contraindicated) Use of dronedarone with vardenafil is contraindicated due to an increased risk for QT prolongation and torsade de pointes. Increased vardenafil exposure may occur due to dronedarone inhibition of CYP3A4. Darunavir; Cobicistat: (Major) Do not use vardenafil orally disintegrating tablets with cobicistat due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets.
Vardenafil is primarily metabolized by CYP3A; ceritinib is a strong CYP3A inhibitor. Use of vardenafil with other strong CYP3A inhibitors increased the AUC of vardenafil by 10 to 16-fold. There may also be an increased potential for QT prolongation. Vardenafil can produce an increase in QTc interval at both therapeutic and supratherapeutic doses. Ceritinib has been reported to cause concentration-dependent QT prolongation.
Periodically monitor ECGs and electrolytes during concurrent use of ceritinib and vardenafil oral tablets. Chloramphenicol: (Major) Do not use vardenafil orally disintegrating tablets with chloramphenicol due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; chloramphenicol is a strong CYP3A4 inhibitor. Chloroquine: (Major) Concomitant use of vardenafil and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Chlorpheniramine; Dextromethorphan; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors.
Chlorpheniramine; Dihydrocodeine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Chlorpheniramine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Chlorpromazine: (Major) Concomitant use of vardenafil and chlorpromazine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Ciprofloxacin: (Major) Do not use vardenafil orally disintegrating tablets with ciprofloxacin due to increased vardenafil exposure; do not exceed buy levitra no prescription a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A and ciprofloxacin is a moderate CYP3A inhibitor. (Major) Do not use vardenafil orally disintegrating tablets with darunavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: (Major) Do not use vardenafil orally disintegrating tablets with cobicistat due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets.
Dasatinib: (Moderate) Concomitant use of vardenafil and dasatinib may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Degarelix: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., degarelix) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Delavirdine: (Major) Do not use vardenafil orally disintegrating tablets with delavirdine due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets.
Vardenafil is primarily metabolized by CYP3A4/5; delavirdine is a strong CYP3A4 inhibitor. Deutetrabenazine: (Moderate) Consider the potential for additive QT effects if vardenafil is administered with deutetrabenazine.
Cisapride: (Contraindicated) Avoid concomitant use of vardenafil and cisapride due to an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. Citalopram: (Major) Concomitant use of citalopram and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Clarithromycin: (Major) Do not use vardenafil orally disintegrating tablets with clarithromycin due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Class IA Antiarrhythmics: (Major) Vardenafil should be avoided in patients taking Class IA antiarrhythmics (disopyramide, procainamide, and quinidine). Class IA antiarrhythmics are associated with QT prolongation and torsade de pointes (TdP).
Therapeutic and supratherapeutic doses of vardenafil produce an increase in QTc interval. The effect of vardenafil on the QT interval should be considered when prescribing the drug. Clofazimine: (Moderate) Concomitant use of clofazimine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Clozapine: (Moderate) Concomitant use of vardenafil and clozapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Cobicistat: (Major) Do not use vardenafil orally disintegrating tablets with cobicistat due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets.
Codeine; Phenylephrine; Promethazine: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Codeine; Promethazine: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Conivaptan: (Major) Do not use vardenafil orally disintegrating tablets with conivaptan due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A; conivaptan is a moderate CYP3A inhibitor. Deutetrabenazine may prolong the QT interval, but the degree of QT prolongation is not clinically significant when deutetrabenazine is administered within the recommended dosage range. Dexmedetomidine: (Moderate) Concomitant use of dexmedetomidine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Dextromethorphan; Diphenhydramine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Dextromethorphan; Guaifenesin; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Dextromethorphan; Quinidine: (Major) Vardenafil should be avoided in patients taking Class levitra 100 mg IA antiarrhythmics (disopyramide, procainamide, and quinidine). Diltiazem: (Major) Do not use vardenafil orally disintegrating tablets with diltiazem due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Additive effects on blood pressure are also possible. Vardenafil is primarily metabolized by CYP3A and diltiazem is a moderate CYP3A inhibitor. Diphenhydramine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Disopyramide: (Major) Vardenafil should be avoided in patients taking Class IA antiarrhythmics (disopyramide, procainamide, and quinidine). Dofetilide: (Major) Concomitant use of vardenafil and dofetilide increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Dolasetron: (Moderate) Concomitant use of vardenafil and dolasetron may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Dolutegravir; Rilpivirine: (Moderate) Concomitant use of vardenafil and rilpivirine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Donepezil: (Moderate) Concomitant use of vardenafil and donepezil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Donepezil; Memantine: (Moderate) Concomitant use of vardenafil and donepezil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Doxazosin: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on alpha-blocker therapy before initiating therapy with the lowest dose of vardenafil. Dronedarone: (Contraindicated) Use of dronedarone with vardenafil is contraindicated due to an increased risk for QT prolongation and torsade de pointes. Increased vardenafil exposure may occur due to dronedarone inhibition of CYP3A4.